Gts Securities LLC Madrigal Pharmaceuticals, Inc. Put Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 13, 2024	BUY	$212.22 - $292.96 $1.63 Million - $2.26 Million	7,700 Added 58.33%	20,900 $4.44 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $1.24 Million - $1.87 Million	-6,400 Reduced 32.65%	13,200 $3.7 Million
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $651,206 - $1.08 Million	-3,800 Reduced 16.24%	19,600 $5.23 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $1.18 Million - $2.32 Million	9,800 Added 72.06%	23,400 $5.41 Million
Q3 2023 Nov 15, 2023	BUY	$146.04 - $225.78 $1.99 Million - $3.07 Million	13,600 New	13,600 $1.99 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.28B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.